OncoGenex to Webcast Discussion of Clinical Development Program and First Quarter 2013 Financial Results on May 2, 2013

  OncoGenex to Webcast Discussion of Clinical Development Program and First
                Quarter 2013 Financial Results on May 2, 2013

PR Newswire

BOTHELL, WA and VANCOUVER, BC, April 25, 2013

BOTHELL, WA and VANCOUVER, BC, April 25, 2013 /PRNewswire/ - OncoGenex
Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's first
quarter 2013 financial results will be released on Thursday, May 2, 2013, and
that the Company will host a conference call and live webcast at 4:30 p.m. ET
that afternoon. Management will provide an overview of clinical development
activities and discuss the company's financial results.

To access the webcast, log on to the Investor Relations page of the OncoGenex
website at www.oncogenex.com. Alternatively, you may access the live
conference call by dialing (877) 606-1416 (U.S. & Canada) or (707) 287-9313
(International). A webcast replay will be available approximately two hours
after the call and will be archived on www.oncogenex.com for 90 days.

ABOUT ONCOGENEX
OncoGenex is a biopharmaceutical company committed to the development and
commercialization of new therapies that address treatment resistance in cancer
patients. OncoGenex has a diverse oncology pipeline, with each product
candidate having a distinct mechanism of action and representing a unique
opportunity for cancer drug development.OncoGenexandTeva Pharmaceutical
Industries Ltd.(NYSE:TEVA) have entered a global collaboration and license
agreement to develop and commercialize OncoGenex' lead drug candidate,
custirsen. Custirsen is currently in Phase 3 clinical development as a
treatment in men with metastatic castrate-resistant prostate cancer and in
patients with advanced, unresectable non-small cell lung cancer. OGX-427 is in
Phase 2 clinical development and OGX-225 is currently in pre-clinical
development. More information is available at www.OncoGenex.com.

SOURCE OncoGenex Pharmaceuticals, Inc.

Contact:

Media Contact:
Jaime Welch
jwelch@oncogenex.com
604-630-5403

Investor Relations Contact:
Susan Specht
sspecht@oncogenex.com
425-686-1535